Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) shares climbed over 10% on Friday morning after the consumer group was cleared in the latest trial on disease risks related to baby formula.
A court in Missouri on Thursday rejected claims that formula made by Reckitts’ Mead Johnson division, alongside Abbott, caused inflammation of the bowel, or necrotizing enterocolitis, which can require invasive surgery.
Plaintiffs had argued Reckitt and Abbott knew of the risks but withheld information.
The case had related to the one infant, with over 1,000 similar suits still pending against the companies.
Reckitt shares climbed 10.7% to 5,186p on Friday.